Multiple Patterns of MDM-2 Deregulation in Human Leukemias: Implications in Leukemogenesis and Prognosis

References

• Chaw-Yuan C., Oliner J.D., Zhan Q., Fomace A.J., Jr., Vogelstein B., Kastan M.B. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc. Natl. Acad. Sci. USA 1994; 91: 2684–2688
   PubMed Web of Science ®Google Scholar
• Levine A.J., Momand J., Finlay C.A. The p53 tumor suppressor gene. Nature 1991; 351: 453–456
   PubMed Web of Science ®Google Scholar
• Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science 1991; 253: 49–53
   PubMed Web of Science ®Google Scholar
• Harris C.C., Hollstein M. Clinical implications of the p53 tumor-suppressor gene. New Engl. J. Med. 1993; 329: 1318–1327
   PubMed Web of Science ®Google Scholar
• Mietz J.A., Unger T., Huibregtse J.M., Howley P.M. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J. 1992; 11: 5013–1520
   PubMed Web of Science ®Google Scholar
• Fakharzadeh S.S., Trusko S.P., George D.L. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 1991; 10: 1565–1569
   PubMed Web of Science ®Google Scholar
• Cahilly-Snyder L., Yang-Feng T., Fracke U., George D.L. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat. Cell Mol. Genet. 1987; 13: 235–244
   PubMedGoogle Scholar
• Momand J., Zambetti G.P., Olson D.C., George D., Levine A.J. The MDM-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237–1245
   PubMed Web of Science ®Google Scholar
• Barak Y., Oren M. Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53-mediated growth arrest. EMBO J. 1992; 11: 2115–2121
   PubMed Web of Science ®Google Scholar
• Hoppe-Seyler F., Butz K. Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53. J. Virol. 1993; 67: 3111–3117
   PubMed Web of Science ®Google Scholar
• Chen J., Marechal V., Levine A.J. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 1993; 13: 4107–4114
   PubMed Web of Science ®Google Scholar
• Wu X., Bayle J.H., Olson D., Levine A.J. The p53-MDM-2 autoregulatory feedback loop. Genes Dev. 1993; 7: 1126–1132
   PubMed Web of Science ®Google Scholar
• Juven T., Barak Y., Zauberman A., George D.L., Oren M. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 1993; 8: 3411–3416
   PubMed Web of Science ®Google Scholar
• Zauberman A., Barak Y., Ragimov N., Levy N., Oren M. Sequence-specific DNA binding by p53: Identification of target sites and lack of binding to p53-MDM2 complexes. EMBO J. 1993; 12: 2799–2808
   PubMed Web of Science ®Google Scholar
• Barak Y., Juven T., Haffner R., Oren M. MDM2 expression is induced by wild type p53 activity. EMBO J. 1993; 2: 461–468
   Google Scholar
• Brown D.R., Deb S., Munoz R.M., Subler M.A., Deb S.P. The tumor suppressor p53 and the oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein. Mol. Cell Biol. 1993; 13: 6849–6857
   PubMed Web of Science ®Google Scholar
• Finlay C.A. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol. Cell Biol. 1993; 13: 301–306
   PubMed Web of Science ®Google Scholar
• Oliner J.D., Kinzler K.W., Meltzer P.S., George D.L., Vogelstein B. Amplification of a gene encoding a p53-as-sociated protein in human sarcomas. Nature 1992; 358: 80–83
   PubMed Web of Science ®Google Scholar
• Leach F.S., Tokino T., Meltzer P., Burrell M., Oliner J.D., Smith S., Hill D.E., Sidransky D., Kinzler K.W., Vogelstein B. p53 mutation and MDM-2 amplification in human soft tissue sarcomas. Cancer Res. 1993; 53: 2231–2234
   PubMed Web of Science ®Google Scholar
• Ladanyi M., Cha C., Lewis R., Jhanwar S.C., Huvos A.G., Healey J.H. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res. 1993; 53: 16–18
   PubMed Web of Science ®Google Scholar
• Bueso-Ramos C.E., Yang Y., de Leon E., McCown P., Stass S.A., Albitar M. The human MDM-2 oncogene is over-expressed in leukemias. Blood 1993; 82: 2617–2623
   PubMed Web of Science ®Google Scholar
• Reifenberger G., Liu L., Ichimura K., Schmidt E.E., Collins V.P. Amplification and overexpression of the MDM-2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. 1993; 53: 2736–2739
   PubMed Web of Science ®Google Scholar
• Olson D.C., Marechal V., Momand J., Chen J., Romocki C., Levine A.J. Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene 1993; 8: 2353–2360
   PubMed Web of Science ®Google Scholar
• Haines D.S., Landers J.E., Engle L.J., George D.L. Physical and functional interaction between wild-type p53 and mdm2 proteins. Mol. Cell Biol. 1994; 14: 1171–1178
   PubMed Web of Science ®Google Scholar
• Wiethege T., Voss B., Muller K.M. Detection of MDM2-proto-oncogene in paraffin embedded human bronchial epithelium. J. Cancer Res. Clin. Oncol. 1994; 120: 252–255
   PubMed Web of Science ®Google Scholar
• Waber P.G., Chen J., Nisen P.D. Infrequency of MDM2 gene amplification in pediatric solid tumors and lack of association with p53 mutations in adult squamous cell carcinomas. Cancer Res. 1993; 53: 6028–6030
   PubMed Web of Science ®Google Scholar
• Kessis T.D., Slebos R.J., Han S.M., Shah K., Bosch X.F., Munoz N., Hedrick L., Cho K.R. p53 gene mutations and MDM2 amplification are uncommon in primary carcinomas of the uterine cervix. Am. J. Pathol. 1993; 143: 1398–1405
   PubMed Web of Science ®Google Scholar
• Esteve A., Lehman T., Jiang W., Weinstein I.B., Harris C.C., Ruol A., Peracchia A., Montesano R., Hollstein M. Correlation of p53 mutations with epidermal growth factor receptor overexpression and absence of mdm2 amplification in human esophageal carcinomas. Mol. Carcinog. 1993; 8: 306–311
   PubMed Web of Science ®Google Scholar
• Kovar H., Auinger A., Jug G., Aryee D., Zoubek A., Salzer-Kuntschik M., Gadner H. Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. Oncogene 1993; 8: 2683–2690
   PubMed Web of Science ®Google Scholar
• Bueso-Ramos C., Manshouri T., Yang Y., Sneige N., Albitar M. MDM-2 deregulation in breast carcinomas and sarcomas. [Abstract]. Mod. Path. 1994; 7: 13
   Google Scholar
• Sheikh M.S., Shao Z.-M., Hussain A., Fontana J.A. The p53-binding protein MDM-2 gene is differentially expressed in human breast carcinoma. Cancer Res. 1993; 53: 3226–3228
   PubMed Web of Science ®Google Scholar
• Albitar M., Katsumata M., Liebhaber S.A. Human ct-globin genes demonstrate autonomous developmental regulation in transgenic mice. Mol. Cell Biol. 1991; 11: 3786
   PubMed Web of Science ®Google Scholar
• Estes P.A., Cook N.E., Liebhaber S.A. A difference in the splicing patterns of the closely related normal and variant human growth hormone gene transcripts is determined by a minimal sequence divergence between two potential splice-acceptor sites. J. Biol. Chem. 1990; 265: 19863
   PubMed Web of Science ®Google Scholar
• Binet J.-L., Catovsky D., Chadra P., Dighiero G., Montserrat T.E., Rai K.R., Sawitsky A. Chronic lymphocytic leukemia: Proposals for a revised prognostic staging system. Br. J. Haematol. 1981; 48: 365–367
   PubMed Web of Science ®Google Scholar
• Samuels B.L., Larson R.A., Le Beau M.M., Daly K.M., Bitter M.A., Vardiman J.W., Barker C.M., Rowley J.D., Golomb H.M. Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo. Leukemia 1988; 2: 79–83
   PubMed Web of Science ®Google Scholar